StockNews.AI
GDRX
StockNews.AI
201 days

GoodRx Announces Date for Fourth Quarter and Full Year 2024 Earnings Release and Conference Call

1. GoodRx will announce Q4 and full-year 2024 results on February 27. 2. Conference call scheduled for February 27 at 5:00 AM PT. 3. GoodRx saved consumers over $75 billion on prescriptions since 2011.

8m saved
Insight
Article

FAQ

Why Neutral?

Upcoming earnings release often leads to price stability or volatility. Investors await results for future guidance.

How important is it?

Earnings announcements are critical for assessing company performance. The stock's valuation may depend on earnings outlook.

Why Short Term?

Earnings results typically impact stock price in the immediate term. Previous earnings announcements have caused short-term fluctuations.

Related Companies

GoodRx Announces Date for Fourth Quarter and Full Year 2024 Earnings Release and Conference Call

SANTA MONICA, Calif.--()--GoodRx Holdings, Inc. (Nasdaq: GDRX) (“GoodRx” or the “Company”), the leading prescription savings platform in the U.S., today announced it will release its fourth quarter and full year 2024 financial results before U.S. markets open on Thursday, February 27, 2025. GoodRx management will also hold a conference call and webcast that morning at 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) to discuss the results and the Company’s business outlook.

To access the conference call, please pre-register using this link. Registrants will receive a confirmation with dial-in details and a unique passcode required to join. The call will also be webcast live on the Company’s investor relations website at https://investors.goodrx.com, where accompanying materials will be posted prior to the conference call.

Approximately one hour after completion of the live call, an archived version of the webcast will be available on the Company’s investor relations website at https://investors.goodrx.com for at least 30 days.

About GoodRx

GoodRx is the leading prescription savings platform in the U.S. Trusted by nearly 30 million consumers and over one million healthcare professionals annually, GoodRx provides access to savings and affordability options for generic and brand-name medications at more than 70,000 pharmacies nationwide, as well as comprehensive healthcare research and information. Since 2011, GoodRx has helped consumers save over $75 billion on the cost of their prescriptions.

GoodRx periodically posts information that may be important to investors on its investor relations website at https://investors.goodrx.com. We intend to use our website as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. Accordingly, investors and potential investors are encouraged to consult GoodRx’s website regularly for important information, in addition to following GoodRx’s press releases, filings with the Securities and Exchange Commission and public conference calls and webcasts. The information contained on, or that may be accessed through, GoodRx’s website is not incorporated by reference into, and is not a part of, this press release.

Contacts

Investor Contact
GoodRx
Aubrey Reynolds
ir@goodrx.com

Media Contact
GoodRx
Lauren Casparis
lcasparis@goodrx.com

Related News